Resistance of prostate cancer to treatment remains a challenge. Surgery, chemotherapy, and androgen deprivation therapy cure most patients with early-stage disease. However, metabolic reprogramming, androgen receptor bypass, and sustained immunotolerance… Click to show full abstract
Resistance of prostate cancer to treatment remains a challenge. Surgery, chemotherapy, and androgen deprivation therapy cure most patients with early-stage disease. However, metabolic reprogramming, androgen receptor bypass, and sustained immunotolerance results in treatment-refractory prostate cancer that progresses to metastatic and lethal stages.
               
Click one of the above tabs to view related content.